Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Shinji Rho"'
Pancreatic tail cancer in the setting of pancreatitis with a review of the literature: A case report
Autor:
Shinji Rho, Sooyoung Martin, Zack Nigogosyan, Vladimir Kushnir, Aaron J. Mintz, Zishuo Ian Hu
Publikováno v:
Clinical Case Reports, Vol 11, Iss 10, Pp n/a-n/a (2023)
Key Clinical Message Environmental risk factors for pancreatic cancer include acute and chronic pancreatitis, obesity, and tobacco use. Differentiating a pancreatic neoplasm in a patient with pancreatitis can be challenging due to their similar prese
Externí odkaz:
https://doaj.org/article/417828d963e7481ebaada0e2dcfb2a74
Publikováno v:
American Heart Journal Plus, Vol 27, Iss , Pp 100283- (2023)
Background: Bevacizumab is a humanized monoclonal anti-VEGF antibody often given in combination with fluorouracil-based chemotherapy as therapy for metastatic colorectal cancer (mCRC). The bleeding and thrombotic event rates in the setting of concurr
Externí odkaz:
https://doaj.org/article/d828e923676f42928d6ce0f25cdcfe62
Autor:
Shinji Rho, Rust, Alyssa, Lydia Zhong Zhong, Lydia, Lee, Koeun, Spencer, Abby, Baggstrom, Maria Q., Bhayani, Rakhee K.
Publikováno v:
Southern Medical Journal; Feb2024, Vol. 117 Issue 2, p98-101, 4p
Publikováno v:
Journal of Clinical Oncology. 41:104-104
104 Background: Bevacizumab is a humanized monoclonal VEGF antibody given in combination with fluorouracil-based chemotherapy for metastatic colorectal cancer (mCRC). Many patients with mCRC also have cardiovascular comorbidities requiring anticoagul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3b928ace5eea4aebcaa26d50a4548a63
https://doi.org/10.1200/jco.2023.41.4_suppl.104
https://doi.org/10.1200/jco.2023.41.4_suppl.104